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Background: The T.E.S.T. program determined the in
vitro activity against methicillinresistant S. aureus and
vancomycin-resistant Enterococcus spp. of TIG and 10
antimicrobials commonly prescribed for serious gram-
positive infections: amoxicillin-clavulanic acid (AUG),
piperacillin-tazobactam (PT), levoﬂoxacin (LVX), ceftriax-
one (CAX), linezolid (LZD), minocycline (MIN), vancomycin
(VAN), ampicillin (AMP), penicillin (P), and meropenem
(MER). Study strains were collected from 697 laboratories
in 55 countries globally throughout 2004-2009.
Methods: A total of 27,846 clinical isolates (10,806 ente-
rococci, 17,040 S. aureus) were identiﬁed to the species
level at each participating site and conﬁrmed by a central
laboratory. Minimum Inhibitory Concentrations (MICs) were
determined by the local laboratory using broth microdilution
panels. Antimicrobial resistance was interpreted according
to CLSI breakpoints with TIG susceptible breakpoints deﬁned
as <0.5 mcg/ml for S. aureus and <0.25 mcg/ml for entero-
cocci.
Results: 12.8% (1,381/10,806) of enterococci were resis-
tant to vancomycin (VRE), and 42.1% (7,174/17,040) of S.
aureus were resistant to oxacillin (MRSA). Among the van-
comycin resistant E. faecium (VREF), % resistant rates to
other study drugs were LVX 99.3, P 98.5, AMP 98.3, VAN 100,
MIN 10.8 and LZD 0.2. Percent resistant rates for MRSA were
P 100, AMP 100, AUG 75.4, LVX 74.9, PT 65.8 CAX 46.5, IMP
24.4, MIN 1.3, LZD 0.0, and VAN 0.0. TIG inhibited 100% of
the enterococci and S. aureus resistant to other drugs. Modal
TIG MICs for VRE/nonVRE were 0.12/0.12, and 0.12/0.12 for
MRSA/MSSA.
Conclusion: TIG retained potent activity against drug-
resistant S. aureus and enterococcal isolates, inhibiting
100% of all strains tested at their deﬁned breakpoints of 0.5
and 0.25mcg/ml, respectively.
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4.003
he survey of risk factors of multi drug resistant of E.
aecalis isolated from clinical samples
. Moniri
Kashan University of Medical Sciences, Kashan, Iran, Islamic
epublic of
Background: During the last decade, enterococci have
ecome important nosocomial pathogens, representing the
econd leading cause of urinary tract infections. This
ncreasing prevalence has been paralleled by the occurrence
f multi-drug resistant (MDR). The aim of this cross-sectional
revalence study was to determine the prevalence and risk
actors of antibiotic resistance of E. faecalis isolated from
linical samples in hospitalized patients in Kashan, Iran.
Methods: This descriptive study was done on clini-
al specimens isolated from hospitalized patients. From
eptember 2007 to 2008, a total of 106 E.faecalis isolates
ere collected from clinical specimens in Kashan hospi-
als. Antimicrobial susceptibility test was determined with
isk diffusion and minimal inhibitory concentration of van-
omycin assayed by E test.
Results: From 128 isolates were found to consist of Ente-
ococcus faecalis 106(82.8%) and Enterococcus faecium 22
17.2%). Resistance rates for E.faecalis were as follows:
rytromycin 52.8%; ciproﬂoxacin 40.6%; gentamicin, 38.7%;
evoﬂoxacin 34%; penicillin, 29.2%; nitrofurantoin 18.9%;
mpicillin, 11.3%; Imipenem 10.4%; and vancomycin, 4.7%
ll isolate were sensitive to linezolid. Multidrug-resistant
MDR) phenotype (resistance to three or more of drugs)
ccurred in 37.7%. Risk factor for a VRE-positive culture
ere antimicrobial usage within 2 months before culture
P = 0.045).
Conclusion: Emergence of multi-resistant E.faecalis and
igh level resistance to vancomycin shown by E.faecalis
trains is of concern because of the decrease in the ther-
peutic options for treatment of infections caused by
nterococci.
oi:10.1016/j.ijid.2010.02.383
4.004
he relationship between macrolide resistance in Strep-
ococcus pneumoniae and consumption of oral macrolides
n Republic of Croatia and City of Zagreb
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Background: The aim of this study was to investigate the
elationship between increased resistance of Streptococcus
neumoniae to macrolides and use of macrolides in Croatia
